BioNTech Buys a Regulatory Shortcut for $205 Million While Roche Picks Up the R&D Tab

BioNTech has agreed to pay $205 million in cash for a priority review voucher from Scholar Rock, a move that puts a hard price tag on the company's ambition to push a late-stage cancer drug toward US approval. The deal, announced alongside a broader reshuffling of its research obligations, shows a company willing to spend real money to compress the timeline between laboratory work and the regulator's desk.

The voucher, issued by the US Food and Drug Administration, applies to a single future marketing application. BioNTech has not named the compound it intends to pair with the ticket, but the company confirmed the intended target is a candidate from its advanced oncology pipeline. Completion hinges on customary closing conditions, including antitrust clearance under the Hart-Scott-Rodino process.

A cash pile with a purpose

The purchase lands against a substantial financial backdrop. As of September 30, 2026, BioNTech reported cash, cash equivalents and securities investments of EUR 16,163.8 million — a reserve that comfortably covers the voucher outlay even as losses mount elsewhere. Over the first nine months of the year, the company posted a net loss of EUR 1.17 billion, a figure that lays bare the cost of its ongoing restructuring.

That picture is complicated by the third quarter, when BioNTech booked a net profit of EUR 184.5 million. Reuters reported that a milestone payment from Bristol Myers Squibb contributed to the result. The swing between a profitable quarter and a nine-month deficit underscores how lumpy individual payments can be — and why investors are focused on the trajectory across reporting periods rather than any single set of figures.

Should investors sell immediately? Or is it worth buying BioNTech?

Revenue pressure is part of the story. In its quarterly update roughly a week ago, BioNTech attributed declining sales mainly to the expected drop in demand for COVID-19 vaccines. That shrinking base makes the deployment of existing capital a central question for shareholders.

Roche takes the bill from 2027

Alongside the voucher agreement, BioNTech exercised an option within its existing collaboration with Roche and Genentech. From January 1, 2027, future research and development costs for the program in question are to be borne principally by Roche/Genentech. BioNTech retains eligibility for licensing payments should development and commercialization succeed, and the ongoing pancreatic cancer trial is set to continue as planned.

Read together, the two moves point in one direction: BioNTech is directing capital toward regulatory preparation while reordering who pays for future development. The voucher gives a late-stage oncology program a shot at a faster review; the Roche option trims the company's forward cost burden on a partnered asset.

The plant closures behind the numbers

Cost discipline extends to manufacturing. According to Reuters, BioNTech will shut its sites in Marburg, Idar-Oberstein and Tübingen by the end of 2028, with annual savings of roughly EUR 500 million expected from 2029. That relief arrives well after the financial commitments already on the books, and its value depends on the closures delivering the savings as advertised.

BioNTech at a turning point? This analysis reveals what investors need to know now.

For investors, two yardsticks now sit side by side. The EUR 16.2 billion reserve funds further steps in the cancer strategy, and the voucher purchase gives that spending a defined destination. A durable economic case, though, only emerges if clinical and regulatory progress converge with a more sustainable earnings profile — and if the pipeline candidate earmarked for the voucher actually reaches the application stage.

BioNTech has set March 2, 2027 as the date for its next scheduled look at the finances, when fourth-quarter and full-year 2026 results are due. Until then, the measure remains straightforward: capital deployed earns its keep only if the oncology pipeline advances toward approval.

Ad

BioNTech Stock: New Analysis - 10 November

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...